FIGURE

Fig. 4

ID

ZDB-FIG-240529-31

Publication

Chen et al., 2024 - Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Spatial metabolomics screened out discriminatory metabolites modulated by wedelolactone (WEL) and demethylwedelolactone (DWEL) on non-alcoholic fatty liver disease (NAFLD). (A) The hematoxylin and eosin (H&E) stain image for model, WEL or DWEL, and normal groups. (B) Metabolite-driven whole-body segmentation analysis based on the matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) data. (C) Whole-body principal component analysis (PCA). (D) Whole-body probabilistic latent semantic analysis (PLSA). (E) Liver specific PLSA analysis. (F?W) MALDI-MS images and expression levels of altered metabolites in zebrafish whole-body section and liver region. ???P < 0.001. CT: control; GPP: glucose phosphate; CSS: cholesterol sulfate; lysoPE: lyso-phosphatidylethanolamine; PE: phosphatidylethanolamine; C26:0-OH-SFT: C26:0-OH sulfatide; PS: phosphatidylserine; LysoPC: lyso-phosphatidylcholine; FAs: fatty acids.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J Pharm Anal